GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 2 465 JPY -2.99% Market Closed
Market Cap: 137.1B JPY
Section:
 

Relative Value

The Relative Value of one GNI Group Ltd stock under the Base Case scenario is 5 447.92 JPY. Compared to the current market price of 2 465 JPY, GNI Group Ltd is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
5 447.92 JPY
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.3
P/S
P/S
Price to Sales
5.3
vs History
44
vs Industry
63
Median 3Y
5.1
Median 5Y
5.3
Industry
8.2
Forward
4.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
20.2
Median 5Y
50.2
Industry
24.2
Forward
9.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
9
Median 3Y
21.5
Median 5Y
27.2
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
9
Median 3Y
-20.8
Median 5Y
-23
Industry
25.5
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
76
vs Industry
30
Median 3Y
3.5
Median 5Y
3.8
Industry
3.3
More Details
4.2
EV/S
EV/S
Enterprise Value to Sales
4.2
vs History
47
vs Industry
56
Median 3Y
4.2
Median 5Y
4.3
Industry
8.6
Forward
3.8
More Details
5.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.8
vs History
31
vs Industry
55
Median 3Y
5.4
Median 5Y
5.4
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
4
Median 3Y
10.4
Median 5Y
21.6
Industry
6.1
Forward
4.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
2
Median 3Y
11.2
Median 5Y
25.8
Industry
6.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
9
Median 3Y
18.1
Median 5Y
23.4
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
6
Median 3Y
-30
Median 5Y
-27.5
Industry
6.8
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
68
vs Industry
47
Median 3Y
2.5
Median 5Y
2.9
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
GNI Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
GNI Group Ltd
TSE:2160
137B JPY 5.3 -195.3 -378.8 -75.5
IL
Can Fite Biopharma Ltd
TASE:CANF
154.5T ILS 56 126 368 -3 854 397.8 -3 782 344.2 -3 773 924.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
393.6B USD 6.6 167.5 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
175.5B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
151.8B USD 5.2 18.8 12.6 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.8 31.3 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.2B USD 5.6 17.5 16.7 18.9
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.2 55.3 56.8
P/S Multiple
Revenue Growth P/S to Growth
JP
GNI Group Ltd
TSE:2160
Average P/S: 8 200 746.4
5.3
41%
0.1
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 126 368
140%
400 902.6
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 067.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
P/E Multiple
Earnings Growth PEG
JP
GNI Group Ltd
TSE:2160
Average P/E: 44.4
Negative Multiple: -195.3
74%
N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 854 397.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.8
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
32.2
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
GNI Group Ltd
TSE:2160
Average EV/EBITDA: 22.1
Negative Multiple: -378.8
81%
N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 782 344.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
55.3
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
GNI Group Ltd
TSE:2160
Average EV/EBIT: 24.2
Negative Multiple: -75.5 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 773 924.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
56.8
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.